Effectiveness and safety of bedaquiline, pretomanid, linezolid and moxifloxacin in drug-resistant tuberculosis patients in selected public hospitals in Ethiopia: a multicenter retrospective cohort study

Abstract Introduction Tuberculosis is a major public health problem, and its treatment has become challenging due to the emergence of drug-resistant tuberculosis. Since 2022, the World Health Organization has called for the rollout of the 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin...

Description complète

Détails bibliographiques

Auteurs principaux:	Bisrat Solomon, Abdurehman Seid, Tigle Nadew, Abel Werku, Tigist Mesfin, Altaye Nigussie, Etalemahu Sebro, Robel Gemechu, Eyerusalem Mekonnen, Bontu Abate, Abraham Eshetu, Workye Tigabie, Melaku Solomon, Haimanot Tadesse Mulu
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2026-03-01
Collection:	BMC Infectious Diseases
Sujets:	Bedaquiline Pretomanid Linezolid Moxifloxacin Drug-resistant tuberculosis Treatment outcome
Accès en ligne:	https://doi.org/10.1186/s12879-026-13135-7
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!